The Phase I clinical trial, known as BD-Ebov, will evaluate the safety of the experimental vaccine and its ability to stimulate immune responses in healthy adult volunteers.

The Bundibugyo strain of the Ebola virus has been devastating the Democratic Republic of the Congo, with no vaccine currently approved to protect against the strain.

The first dose of the rapidly developed vaccine was administered to Ed Hunt, a 37-year-old volunteer, said Britain’s Oxford University.